Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe

Paul Hagedoorn, Floris Grasmeijer, Marcel Hoppentocht, Onno Akkerman, Henderik Frijlink, Anne de Boer
European Respiratory Journal 2016 48: PA2561; DOI: 10.1183/13993003.congress-2016.PA2561
Paul Hagedoorn
11Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Floris Grasmeijer
11Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Hoppentocht
11Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Onno Akkerman
2Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henderik Frijlink
11Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne de Boer
11Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 48 no. suppl 60
DOI 
https://doi.org/10.1183/13993003.congress-2016.PA2561

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online November 8, 2016.

Copyright & Usage 
Copyright ©the authors 2016

Author Information

  1. Paul Hagedoorn1,
  2. Floris Grasmeijer1,
  3. Marcel Hoppentocht1,
  4. Onno Akkerman2,
  5. Henderik Frijlink1 and
  6. Anne de Boer1
  1. 11Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands
  2. 2Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Article usage

Article usage: November 2016 to February 2023

AbstractFullPdf
Nov 20161900
Dec 20164700
Jan 20172100
Feb 20172500
Mar 20172200
Apr 20172200
May 20172200
Jun 20171800
Jul 20171300
Aug 20171100
Sep 20171100
Oct 20171700
Nov 20171600
Dec 20172500
Jan 20182000
Feb 20181700
Mar 20181000
Apr 20181400
May 20182400
Jun 20181500
Jul 20181200
Aug 20183100
Sep 20181000
Oct 20181600
Nov 20181000
Dec 2018500
Jan 20191200
Feb 20191000
Mar 20191500
Apr 2019400
May 20192900
Jun 20191500
Jul 20194400
Aug 20191500
Sep 20192000
Oct 20191600
Nov 2019800
Dec 20191800
Jan 20203000
Feb 20202100
Mar 20202400
Apr 20202200
May 20202100
Jun 20201000
Jul 20202200
Aug 20202200
Sep 20201900
Oct 20203400
Nov 20201600
Dec 20201900
Jan 2021800
Feb 20211900
Mar 20211800
Apr 2021900
May 20211200
Jun 20211200
Jul 20211500
Aug 20211400
Sep 20211300
Oct 20211400
Nov 20211600
Dec 20211100
Jan 20222800
Feb 2022700
Mar 2022400
Apr 20221300
May 20221100
Jun 20221200
Jul 2022800
Aug 20221400
Sep 2022400
Oct 20221100
Nov 2022900
Dec 2022400
Jan 2023700
Feb 2023900

Altmetrics

Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe
Paul Hagedoorn, Floris Grasmeijer, Marcel Hoppentocht, Onno Akkerman, Henderik Frijlink, Anne de Boer
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2561; DOI: 10.1183/13993003.congress-2016.PA2561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe
Paul Hagedoorn, Floris Grasmeijer, Marcel Hoppentocht, Onno Akkerman, Henderik Frijlink, Anne de Boer
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2561; DOI: 10.1183/13993003.congress-2016.PA2561
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Risk factors and treatment outcomes in patients with chronic pulmonary aspergillosis
  • Microbiological spectrum and susceptibility pattern of clinical isolates from the Respiratory Intensive and Post-Intensive Care Unit of University Hospital Center Zagreb, Croatia
  • Baseline incidence of respiratory viruses in asymptomatic patients
Show more 10.1 Respiratory Infections

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society